Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Tuberous Sclerosis Alliance and Nobelpharma to Celebrate Rare Disease Day with New Partnership prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.